Accera Appoints Dr. Judith Walker as Chief Medical Officer

Accera, Inc., an Inventages portfolio company, today announced the appointment of Judith Walker, M.D., F.R.C.P.(C), as Chief Medical Officer. Dr. Walker joins Accera from QuintilesIMS where she held the position of Vice President of Product Development, providing leadership for the global clinical development of drugs in the areas of neurology and pain.

“Dr. Walker brings to Accera over 20 years of experience in the global biopharmaceutical industry,” said Accera’s president and CEO, Charles Stacey, M.D. “Her wealth of expertise in neurology drug development will be invaluable as we advance our metabolic approach to the treatment of Alzheimer’s disease into the final stage. Dr. Walker will lead the progression of our newly formulated lead compound in Alzheimer’s and help build out our pipeline of drugs in the CNS space.”
Prior to QuintilesIMS, Dr. Walker served as Senior Director of Medical Affairs at Teva Neuroscience, a division of Teva Pharmaceuticals. Before Teva Neuroscience, Dr. Walker held leadership roles in global product and global clinical development in neurology at Serono International (Merck KGaA). Dr. Walker continues to serve on the boards of Great Lakes Neuroscience and the pharmaceutical advisory board of the non-profit Accelerated Cure Project. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Walker received her medical degree from the University of Montréal and completed her residency in neurology at the University of Western Ontario.

“Accera has one of the few drugs in late-stage development for Alzheimer’s disease which addresses a differentiated and well-validated target,” said Dr. Walker. “I am delighted to be joining Accera at this exciting time in the program.”

About Accera
Accera, Inc. is a CNS therapeutics company based in Colorado, USA. The company’s proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer’s disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company’s management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera’s lead candidate is a small molecule drug compound in Phase 3 clinical development in patients with mild to moderate Alzheimer’s disease. For more information, visit www.accerapharma.com or follow Accera on Twitter at twitter.com/accerainc.